Screening and risk stratification of patients with the metabolic syndrome and diabetes

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 2, 2006, Pages 181-190

  Wong, Nathan D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coronary heart disease; Diabetes; Epidemiology; Metabolic syndrome; Prevention; Risk assessment; Screening; Subclinical atherosclerosis

Indexed keywords

C REACTIVE PROTEIN; LIPID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ALGORITHM; ANKLE BRACHIAL INDEX; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DEVELOPED COUNTRY; DIABETES MELLITUS; ECHOGRAPHY; HUMAN; METABOLIC SYNDROME X; MORTALITY; PATIENT CARE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING; BLOOD; DIABETIC ANGIOPATHY; FEMALE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; PREVALENCE; RISK FACTORS;

EID: 33646194018     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.2.181     Document Type: Review

References (42)

1. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation Among Adults in the US Diabetes Care 28, 2745-2749 (2005)
2. Ko GT, Cockram, CS, Chow CC et al. High prevalence of metabolic syndrome in Hong Kong Chinese - comparison of three diagnostic criteria. Diab. Res. Clin. Pract. 69, 160-168 (2005).
3. Tillin T, Forhouhi N, Johnston DG et al. Metabolic syndrome and coronary heart disease in South Asians, African-Caribbeans and white Europeans: a UK population-based cross-sectionai study. Dibetologia 48, 649-656 (2005).
4. Hu G, Qiao Q, Tuomilehto J et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch. Intern. Med. 164. 1066-1076 (2004).
5. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/Nationai Heart Lung and Blood Institute Scientific Statement. Circulation 112, 2735-2752 (2005).
6. Khan R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical reappraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28, 2289-2304 (2005).
7. Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110, 1239-1244 (2002).
8. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Cirrulation 108, 414-419 (2003).
9. Isomaa B, Almgren P Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24, 683-689 (2001).
10. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28, 1769-78 (2005).
11. Wong ND, Pio JR, Franklin SS et al. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am. J. Caidio. 91, 1421-1426 (2003).
12. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 106, 3143-3421 (2002).
13. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229-234 (1998).
14. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52(5), 1210-1214 (2004).
15. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP; San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110, 1251-1257 (2004).
16. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin. Sci, 101, 671-679 (2001).
17. Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet. Med. 21, 238-245 (2004).
18. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. Diabetic Medicine 22, 554-562 (2005).
19. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107, 391-397 (2003).
20. Rutter MK, Meigs JB, Sullivan LM et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring study. Circulation 110, 380-385 (2004).
21. Malik S, Wong ND, Frankin SS, Pio, J, Fairchild C, Chen R. Cardiovascular disease in US persons with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 28, 690-3 (2005).
22. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109, 2818-2825(2004).
23. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499-511(2004) (2003).
24. O'Leary DH, Polak JF, Kronmal RA et al. Cardiovascular Health Study Collaborative Research Group: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N. Engl. J. Med. 340, 14-22 (1999).
25. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med 326, 381-386 (1992).
26. Criqui MH, Langer RD, Fronek A, Feigelson HS: Coronary disease and stroke in patients with large vessel peripheral arterial disease. Drugs 42(Suppl. 5), 16-21 (1991).
27. Wong ND, Hsu JC, Detrano RC, Diamond G, Eisenberg H, Gardin JM. Coronary artery calcium evaluation by electron beam computed tomography: relation to new cardiovascular events. Am. J. Cardiol. 86, 495-498 (2000).
28. Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD. Prediction of coronary events with electron beam computed tomography. J. Am. Coll. Cardiol. 36, 1253-1260 (2000).
29. Kondos GT, Hoff JA Sevrukov A et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 635 initially asymptomatic low to intermediate-risk adults. Circulation 107, 2571-2576(2003).
30. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium for all-cause mortality. Radiology 228, 826-833 (2003).
31. O'Malley PG, Taylor AJ, Jackson JL, Doherty TM, Detrano RC. Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asyptomatic populations. Am. J. Cardiol. 85, 945-948(2000).
32. Wilson PWF, Smith SC, Blumenthal RS, Burke GL, Wong ND. Task Force 4 - How do we select patients for atherosclerosis imaging? In: 34th Bethesda Conference: can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease. J. Am. Coll. Cardiol. 41, 1898-1906 (2003).
33. Wong ND, Sciammarella MG, Polk D et al. The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium. J. Am. Coll. Cardiol, 41, 1547-1553 (2003).
34. Ellison RC, Zhang Y, Wagenknect LE et al. Relation of the metabolic syndrome to calcified atherosclerotic plaque in the coronary arteries and aorta. Am. J. Cardiol. 95, 1180-1186 (2005).
35. Kullo IJ, Cassidy AE, Peyser PA et al. Association between metabolic syndrome and subclinical coronary atherosclerosis in asymptomatic adults. Am. J. Cardiol. 94, 1554-1558 (2004)
36. Wong ND, Rozanski AR, Gransar H et al Metabolic syndrome increases the likelihood of inducible myocardial ischemia among patients with subclinical atherosclerosis. Diabetes Care 28, 1445-1350 (2005).
37. Ahluwalia N, Drouet L, Ruidavets; JB et al. Metabolic syndrome is associated with markers of subclinical atherosclerosis in a French population-based sample. Atherosclerosis 26 (Epub. in advance) (2005).
38. Burchfiel CM, Skelton TN, Andrew ME. Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 112, 819-827.
39. McNeill AM, Rosamond WD, Girman CJ et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am. J. Cardiol. 94, 1249-1254 (2004).
40. Tzou WS, Douglas PS, Srinivasan SR. Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J. Am. Coll. Cardiol. 46, 457-463 (2005).
41. McMahon LF Jr, Hayward R, Saint S et al. Univariate solutions in a multivariate world: can we afford to practice as in the 'good old days? Am. J. Manag. Care 11, 473-476 (2005).
42. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ324, 1570-1576 (2002).